Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist-Reference-Cited by-同舟云学术

Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist

Published:2018-11-14 Issue:467 Volume:10 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Buckley Stephen T.¹^ORCID,Bækdal Tine A.²,Vegge Andreas¹,Maarbjerg Stine J.²,Pyke Charles¹,Ahnfelt-Rønne Jonas¹,Madsen Kim G.¹^ORCID,Schéele Susanne G.¹^ORCID,Alanentalo Tomas¹,Kirk Rikke K.¹,Pedersen Betty L.¹,Skyggebjerg Rikke B.¹,Benie Andrew J.¹^ORCID,Strauss Holger M.¹,Wahlund Per-Olof¹^ORCID,Bjerregaard Simon¹,Farkas Erzsébet³,Fekete Csaba³⁴^ORCID,Søndergaard Flemming L.²,Borregaard Jeanett²,Hartoft-Nielsen Marie-Louise²,Knudsen Lotte Bjerre¹

Affiliation:

1. Novo Nordisk A/S, 2760 Måløv, Denmark.

2. Novo Nordisk A/S, 2860 Søborg, Denmark.

3. Department of Endocrine Neurobiology, Institute of Experimental Medicine, Hungarian Academy of Sciences, 1083 Budapest, Hungary.

4. Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Tupper Research Institute, Tufts Medical Center, Boston, MA 02111, USA.

Abstract

An orally delivered GLP-1 analog coformulated with the absorption enhancer SNAC achieves transcellular-directed absorption in the stomach.

Funder

Novo Nordisk

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference42 articles.

1. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

2. Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial

3. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss